Patents by Inventor Dennis Kaetzel

Dennis Kaetzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures
    Patent number: 10525103
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: January 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann
  • Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures
    Patent number: 10391145
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann
  • COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES
    Publication number: 20190134155
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicant: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullman
  • COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES
    Publication number: 20160375097
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Application
    Filed: March 6, 2015
    Publication date: December 29, 2016
    Applicant: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann